The role of everolimus in liver transplantation

Rainer Ganschow1
Jörg-Matthias Pollok2
Martin Jankofsky3
Guido Junge4
1Department of Pediatrics, University of Bonn, Bonn, Germany
2Integrated Hospital Care, Novartis Pharma AG, Basel, Switzerland

Abstract: During the last 5 decades, liver transplantation has witnessed rapid development in terms of both technical and pharmacologic advances. Since their discovery, calcineurin inhibitors (CNIs) have remained the standard of care for immunosuppression therapy in liver transplantation, improving both patient and graft survival. However, adverse events, particularly posttransplant nephrotoxicity, associated with long-term CNI use have necessitated the development of alternate treatment approaches. These include combination therapy with a CNI and the inosine monophosphate dehydrogenase inhibitor mycophenolic acid and use of mammalian target of rapamycin (mTOR) inhibitors. Everolimus, a 40-O-(2-hydroxyethyl) derivative of mTOR inhibitor sirolimus, has a distinct pharmacokinetic profile. Several studies have assessed the role of everolimus in liver transplant recipients in combination with CNI reduction or as a CNI withdrawal strategy. The efficacy of everolimus-based immunosuppressive therapy has been demonstrated in both de novo and maintenance liver transplant recipients. A pivotal study in 719 de novo liver transplant recipients formed the basis of the recent approval of everolimus in combination with steroids and reduced-dose tacrolimus in liver transplantation. In this study, everolimus introduced at 30 days posttransplantation in combination with reduced-dose tacrolimus (exposure reduced by 39%) showed comparable efficacy (composite efficacy failure rate of treated biopsy-proven acute rejection, graft loss, or death) and achieved superior renal function as early as month 1 and maintained it over 2 years versus standard exposure tacrolimus. This review provides an overview of the efficacy and safety of everolimus-based regimens in liver transplantation in the de novo and maintenance settings, as well as in special populations such as patients with hepatocellular carcinoma recurrence, hepatitis C virus-positive patients, and pediatric transplant recipients. We also provide an overview of ongoing studies and discuss potential expansion of the role for everolimus in these settings.

Keywords: mTOR inhibitors, everolimus, liver transplantation, efficacy, safety

Introduction to liver transplantation

During the 5 decades since the first human liver transplant in 1963,1 there have been a number of important technical and pharmacological advances in liver transplantation. Early results were poor, with a survival of only 13 months,2,3 but they started to improve after the introduction of more-effective immunosuppressive agents. Today, better recipient selection (based on Model for End-Stage Liver Disease score4 and Milan criteria)5,6 and evolving surgical techniques and perioperative management have resulted in improved short-term outcomes. Surgical advances include reduced-sized liver grafts in 1981,7 followed by split liver transplantation in 19888 and the use of living donors in the 1990s.9,10 Indications for liver transplantation have also changed over time. In addition to the common indications, including acute and chronic conditions such as
chronic viral hepatitis C, hepatitis B, autoimmune conditions (primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis), and hepatic malignancies, patients with metabolic conditions such as nonalcoholic steatohepatitis are now more frequently being wait-listed for liver transplantation.11

Immunosuppression after liver transplantation in the 1960s and 1970s mainly included use of chemical agents such as purine analog azathioprine and steroids. With this regimen, 1- and 5-year survival rates were 32.9% and 20.0%, respectively.12 The introduction of cyclosporine in the early 1980s significantly improved both graft and patient survival,12,13 with a cyclosporine-based regimen achieving 1- and 5-year survival rates of 69.7% and 62.8%, respectively.12

Despite the technological and pharmacological advances and improvement in short-term outcomes, management issues associated with surgery, immunosuppression, and recurrence of disease still remain a challenge in liver transplantation. Although the incidence of acute rejection has declined over the years as immunosuppressive regimens have developed, other complications associated with the surgical procedure or immunosuppression, such as hepatic artery thrombosis (HAT), biliary tract complications, and infections,14,15 are of concern. Potential problems related to chronic immunosuppression include systemic events (pulmonary, renal, or neurological) and malignancy.14 In addition, recurrence of original diseases such as hepatitis C virus (HCV) infection, hepatocellular carcinoma (HCC), and primary sclerosing cholangitis represents a major clinical obstacle. Recurrent HCV infection after liver transplantation is universal and is associated with accelerated liver fibrogenesis, leading to allograft cirrhosis in at least 30% of patients within 5 years of transplantation.16,17 Posttransplant HCC recurrence has been reported in up to 20% of patients;18 although lower incidence (<10%) has been reported among the patients within the Milan criteria.19,20 Recurrence of primary sclerosing cholangitis has been reported in 10%–38.7% of liver transplant recipients.21

Role of immunosuppression in liver transplantation
At this time, the goal of immunosuppression in liver transplantation is to maintain graft function with a low rate of acute rejection while minimizing drug-related adverse effects. Under-immunosuppression can lead to an increased risk for graft rejection, whereas over-immunosuppression is associated with an increased risk for adverse events; notably, infections and malignancies. Thus, providing optimal immunosuppression is key. Calcineurin inhibitors (CNIs) represent the mainstay of immunosuppressive therapy in liver transplantation. With the introduction of CNI therapy, acute rejection rates have declined considerably. However, prolonged CNI exposure is associated with nephrotoxicity,22,23 neurotoxicity,24–26 increased risk for malignancies,27–29 metabolic complications,30,31 and hypertension.32

CNI-induced nephrotoxicity is the leading cause of renal dysfunction after liver transplantation22,23,33 and has been associated with significant morbidity and mortality.22,23 Incidence rates as high as 18.1% by 5 years posttransplant have been observed,23 and in the Model for End-Stage Liver Disease era, the 5-year cumulative incidence of chronic renal failure has been reported to be 22%.34 Such high rates of nephrotoxicity, along with steroid-induced growth retardation, can have a major effect, particularly in pediatric recipients,35–37 who have a longer exposure to immunosuppressive therapy. Indeed, renal dysfunction has been reported in as many as 32% of pediatric liver transplant recipients at an average follow-up of 7.6 years after transplantation.38 In addition, CNI-induced neurological adverse effects have been reported in up to 40% of patients receiving cyclosporine.39 Both cyclosporine and tacrolimus are associated with an increased risk for HCC recurrence in liver transplant recipients.39–40 Metabolic adverse events, such as hyperlipidemia and new-onset diabetes mellitus (NODM), are also common with CNIs,40 although the incidence rates vary; for example, a significantly higher incidence of NODM has been reported with tacrolimus than with cyclosporine.41

Delaying the introduction of CNIs or reducing CNI exposure are the strategies that have been explored to lower the adverse events associated with this class of drug. One approach in adult recipients has been to administer short-term induction therapy (polyclonal or monoclonal antibodies, or interleukin 2 receptor antibodies such as basiliximab) with delayed introduction of CNIs.41–44 Use of induction therapy is also known to reduce the rates of acute rejection in children receiving CNI-based immunosuppression.45–48

Other treatment strategies focus on optimizing immune modulation by combination immunosuppressants with different mechanisms of action to minimize the adverse events while maintaining immunosuppressive efficacy.49 Maintenance immunosuppression in liver transplant recipients typically includes combinations of drugs that target complementary pathways, most frequently a CNI plus an inosine monophosphate dehydrogenase inhibitor, with or without steroids.50
Unlike the wide array of immunosuppressants approved for use in kidney transplantation, until recently, only the CNIs cyclosporine and tacrolimus, as well as mycophenolate mofetil, were approved for liver transplantation; moreover, cyclosporine plus mycophenolate mofetil was the only combination regimen approved in this setting.51-53 Development of the mammalian target of rapamycin (mTOR) inhibitors everolimus and sirolimus generated considerable interest among transplant physicians, especially in view of their potential to reduce or eliminate CNIs. The mTOR inhibitors exert their immunosuppressive effect via a separate mechanism and exhibit a different pharmacological profile to CNIs and inosine monophosphate dehydrogenase inhibitors, providing a new option in the immunosuppressive armamentarium for transplant recipients. Of the two mTOR inhibitors, sirolimus was introduced first in the late 1990s for prophylaxis of rejection in solid organ transplantation. Everolimus is a 40-O-(2-hydroxyethyl) derivative,54 which was developed to improve the pharmacokinetic profile of sirolimus. The hydroxyethyl group provides a pharmacokinetic advantage, conferring faster absorption and a shorter half-life than sirolimus.55-57 Unlike sirolimus, no loading dose is required for everolimus, and the twice-daily dosing schedule allows better dose adjustments.57

Everolimus (in combination with cyclosporine and corticosteroids) was first approved in 2003 for the prophylaxis of organ rejection in kidney and heart transplant recipients in many European countries, followed by a US Food and Drug Administration (FDA) approval for kidney transplantation in 2010. Everolimus, in combination with reduced-dose tacrolimus and steroids, is the first approval by US FDA for an immunosuppressive agent in liver transplantation for more than a decade.58 Of note, sirolimus is not approved for use in liver transplantation and carries a black box warning from the US FDA because of a high incidence of HAT, graft loss, and death.59 The review focuses on the use of everolimus-based immunosuppression in liver transplantation.

**Everolimus**

**Mechanism of action**

At an intracellular level, everolimus binds to FKB12. The resulting complex blocks the activation of the TOR complex1 complex, a cycle-specific kinase that activates p70 ribosomal S6 kinase (p70S6k).60,61 Inhibition of the mTOR pathway prevents progression of the cell cycle from G1 into the S phase, thus suppressing interleukin (IL)-driven T-cell differentiation. Inactivation of the p70S6k in lymphocytes results in selective inhibition of ribosomal protein synthesis, thereby deactivating the immune response.60,62 mTOR plays an important role in several physiological processes, such that inhibition by everolimus also leads to various downstream consequences via an effect on nonimmune cells such as vascular smooth muscle cells, tubular epithelial cells, and fibroblasts. Antiangiogenic activity of mTOR inhibitors has been associated with a decrease in vascular endothelial growth factor production.63-65 Anticancer effects are mediated via the phosphatidylinositol 3-kinase/AKT/mTOR pathway,66 and antifibrotic activity has been linked to the mTOR/p70S6k/procollagen 1 pathway.67

Everolimus is metabolized in the gut and liver by CYP3A4; therefore, concomitant administration of other CYP3A inhibitors such as verapamil, ketoconazole, and erythromycin may lead to drug–drug interactions.68-70 Routine therapeutic drug monitoring is recommended to guide dose adjustments when everolimus is coadministered with other CYP3A inhibitors.71 Everolimus also has shown synergism with cyclosporine in terms of the immunosuppressive effect.72,73 Tacrolimus and cyclosporine differ significantly in their interaction when coadministered with everolimus. Lower doses of everolimus are needed when coadministered with cyclosporine (so that reducing the dose of cyclosporine may decrease everolimus concentrations), whereas tacrolimus has a minimal effect on everolimus blood levels.73

**Efficacy studies**

The efficacy of everolimus has been demonstrated in de novo and maintenance liver transplant recipients.74-78 A summary of key randomized controlled trials of everolimus in liver transplant recipients is presented in Table 1.

Phase 1 and dose-finding studies of everolimus in combination with standard-dose cyclosporine in de novo liver transplant recipients revealed that everolimus at a dose of 2–4 mg/day was well-tolerated in this population.80,81

In maintenance liver transplant recipients, a feasibility study (N=40) showed that conversion from CNI to everolimus with or without antimetabolite therapy was feasible in 75% of patients. This study also found that the improvement in renal function after conversion to everolimus, more than 60% of patients were CNI-free, and that conversion was associated with a low risk for acute rejection. In addition, a significant improvement in renal function was observed: mean estimated glomerular filtration rate (eGFR) increased...
**Table 1** Summary of randomized controlled trials of everolimus in liver transplantation

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>Study population</th>
<th>Treatment groups</th>
<th>Key results</th>
<th>Renal function</th>
<th>Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Simone et al†,</td>
<td>24-month prospective,</td>
<td>De novo liver transplant recipients</td>
<td>EVR + reduced TAC (N=245): EVR C0 3–8 ng/mL and TAC C0 3–5 ng/mL TAC control (N=243): TAC C0 8–12 ng/mL until month 4 and C0 6–10 ng/mL thereafter TAC-withdrawal (N=231): EVR C0 6–12 ng/mL with CNI elimination at month 4</td>
<td>Comparable composite efficacy failure rate at month 12 and month 24 between EVR + reduced TAC and TAC control</td>
<td>Superior renal function assessed by eGFR in EVR + reduced TAC group compared with TAC control</td>
<td>Higher incidence of hyperlipidemia, neutropenia, peripheral edema, stomatitis/mouth ulceration, and thrombocytopenia in the EVR group</td>
</tr>
<tr>
<td>Saliba et al†††</td>
<td>randomized, multicenter, open-label study</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(H2304)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fischer et al†††</td>
<td>12-month prospective,</td>
<td>De novo liver transplant recipients</td>
<td>EVR (N=101): EVR C0 5–12 ng/mL (C0 8–12 ng/mL with CsA) Control (N=102): CNI-based regimen</td>
<td>Similar incidence of graft loss and rejection episodes</td>
<td>No significant difference in mean calculated GFR (Cockcroft-Gault) at 11 months post-randomization*</td>
<td>Higher incidence of infections, leukopenia, hyperlipidemia, anemia, and arterial hypertension in the EVR group</td>
</tr>
<tr>
<td>(PROTECT)</td>
<td>randomized, multicenter, open-label study</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Masetti et al†††</td>
<td>12-month, prospective,</td>
<td>De novo liver transplant recipients</td>
<td>Early CNI withdrawal followed by EVR monotherapy (N=52): C0 6–10 ng/mL until day 30, 8–12 ng/mL until the end of month 6 and 6–10 ng/mL thereafter Standard CsA (N=26): C0 225±25 ng/mL until day 30, then 200±25 ng/mL until the end of month 6 and 150±25 ng/mL thereafter</td>
<td>Similar incidence of acute rejection</td>
<td>Significant improvement in renal function (eGFR, Modification of Diet in Renal Disease 4) at Month 12 in the EVR group versus CsA group*</td>
<td>Higher incidence of incisional hernia, elevated serum cholesterol, high-density lipoprotein and low-density lipoprotein, and inferior limbs edema in the EVR group</td>
</tr>
<tr>
<td></td>
<td>randomized, single-center, open-label study</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>De Simone et al††</td>
<td>6-month prospective,</td>
<td>Maintenance liver transplant recipients</td>
<td>EVR with CNI reduction or elimination (N=72): EVR (C0 3–8 ng/mL) plus CNI (C0 3–5 ng/mL) or EVR (C0 6–12 ng/mL) with CNI elimination CNI (N=73): standard exposure TAC or CsA</td>
<td>Low incidence of efficacy failure events in both the groups</td>
<td>Similar mean change in creatinine clearance (Cockcroft-Gault) from baseline to month 6*</td>
<td>Higher incidence of hyperlipidemia, mouth ulceration, increased hepatitis C virus viral titer, dry skin, eczema, and rash in the EVR group</td>
</tr>
<tr>
<td></td>
<td>randomized, multicenter, open-label study (with additional 6-month follow-up)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levy et al†††</td>
<td>12-month randomized,</td>
<td>De novo liver transplant recipients</td>
<td>EVR 1 mg/day + CsA (N=28) EVR 2 mg/day + CsA (N=30) EVR 4 mg/day + CsA (N=31) Placebo + CsA (N=30)</td>
<td>Similar incidence of composite efficacy failure between groups and lower rate of treated acute rejections in the EVR group versus placebo</td>
<td>Stable serum creatinine and creatinine clearance from month 1 onward</td>
<td>Higher incidence of anemia, tachycardia, constipation, edema, elevated blood creatinine, and agitation in the EVR group. More frequent EVR-related adverse events with higher doses</td>
</tr>
<tr>
<td>(B158 study)</td>
<td>double-blind, placebo-controlled study (with 24-month open-label extension)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** *Indicates primary endpoint. Composite efficacy failure = treated biopsy-proven acute rejection, graft loss, or death.  
**Abbreviations:** EVR, everolimus; TAC, tacrolimus; C0, trough level; CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; PROTECT, Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy; CsA, cyclosporine.
from 64.2±30 mL/minute at day 0 to 68.4±32.5 mL/minute at month 12 (P=0.007). In a randomized, open-label, multicenter study by De Simone et al, 145 maintenance liver transplant recipients (time since transplantation >3 years) with CNI-related renal impairment were randomized either to start concentration-controlled everolimus with CNI reduction or discontinuation or to continue a standard-exposure CNI regimen. Everolimus was compared with the standard-exposure CNI. Results showed that everolimus allows CNI withdrawal or reduction without compromising efficacy. CNI elimination was achieved in 80% and 85% of patients at 6 and 12 months, respectively, with a very low incidence of biopsy-proven acute rejection (BPAR). The incidence of BPAR was identical (1.4%) at month 6 in both treatment groups and was 4.2% and 1.3% at month 12 in the everolimus and standard-exposure CNI groups, respectively. Despite safe conversion to everolimus without compromising efficacy, no significant improvement in renal function was observed. Low CNI exposure at baseline in both everolimus and standard-exposure CNI groups, higher CNI dose reductions in the control group, and the extended time since transplantation (>3 years) were identified as the main contributing factors. The authors, therefore, hypothesized that earlier conversion to everolimus with subsequent CNI reduction may provide an increased benefit for renal function.

In de novo liver transplant recipients, Masetti et al described the use of everolimus in a single-center, randomized, phase 2 trial. After treatment with cyclosporine for first 10 days, 78 liver transplant recipients were randomized either to receive everolimus plus cyclosporine for up to 30 days, followed by everolimus monotherapy, or to continue receiving cyclosporine with or without mycophenolate mofetil, depending on the presence of chronic kidney disease. Early withdrawal of cyclosporine with subsequent everolimus monotherapy was associated with a significant improvement in renal function (mean eGFR–Modification of Diet in Renal Disease [MDRD]) at month 12 was 87.7±26.1 mL/minute versus 59.9±12.6 mL/minute in the cyclosporine group; P<0.001). Furthermore, a higher proportion of patients had stage 3 or higher chronic kidney disease (eGFR <60 mL/minute) in the cyclosporine group versus in the everolimus group (52.2% versus 15.4%; P=0.005). Comparable rates of BPAR (5.7% versus 7.7%) were observed in both treatment groups (Figure 1).

PROTECT, another study employing early conversion to everolimus, was a multicenter, open-label, randomized controlled trial in which 203 de novo liver transplant recipients were randomized at 30–60 days posttransplant to either continue a CNI-based regimen or start everolimus with CNI discontinuation. All patients received basiliximab induction, with or without maintenance corticosteroids. Results showed that conversion from a CNI-based to an everolimus-based regimen can be achieved safely, with beneficial effects on renal function. The incidences of a composite efficacy failure endpoint (BPAR, graft loss, death, or loss to follow-up; everolimus, 20.8%, versus CNI, 20.4%) and BPAR (everolimus, 17.7%, versus CNI, 15.3%) were similar between the two treatment groups. At month 11, GFR estimated using the Modification of Diet in Renal Disease formula (considered the appropriate formula for GFR calculation in liver transplant recipients) showed a significant difference between the everolimus and CNI groups (least square [LS] mean difference of 7.8 mL/minute in favor of everolimus; P=0.021). However, using the Cockroft-Gault formula, the mean difference in GFR between the everolimus and CNI groups (2.9 mL/minute; P=0.46) did not reach the protocol-defined superiority criterion (a between-group difference in GFR of 8 mL/minute). In the pivotal registration study (H2304) that led to everolimus approval in liver transplantation, 719 de novo liver transplant recipients were randomized after a 30±5-day run-in period to everolimus plus reduced tacrolimus, standard-exposure tacrolimus, or everolimus with tacrolimus elimination. Tacrolimus exposure was reduced by 39% in the everolimus plus reduced tacrolimus group compared with in the standard-exposure tacrolimus group. Everolimus with reduced tacrolimus proved to be noninferior to standard-exposure tacrolimus, showing a numerically lower incidence rate of the primary endpoint of efficacy failure, defined as
treated BPAR, graft loss, or death at month 12. The study also showed that immunosuppression with everolimus plus reduced tacrolimus was associated with significantly fewer BPAR episodes than standard-exposure tacrolimus (4.1% versus 10.7%; $P=0.005$ at month 12 and 6.1% versus 13.3%; $P=0.010$ at month 24), and that BPAR was less severe. A high incidence of acute rejections led to premature termination of enrollment to the tacrolimus elimination group, in which tacrolimus was completely withdrawn by the end of month 4 after transplantation. Most of these acute rejections occurred around the time of tacrolimus elimination. Abrupt cessation of tacrolimus might have contributed to the high rate of acute rejections. The authors speculated that an mTOR inhibitor regimen without induction therapy and with no additional immunosuppressive comedication might not be a viable option until 90 days after liver transplantation. In terms of renal function, everolimus plus reduced tacrolimus was associated with superior renal function (eGFR [MDRD-4]) at 12 and 24 months compared with standard tacrolimus (Figure 2). The improvement in eGFR from randomization to month 24 was significantly higher in the everolimus plus reduced tacrolimus group versus in the standard tacrolimus group (mean difference, 6.7 mL/minute/1.73 m²; 97.5% confidence interval, 1.9–11.4 mL/minute/1.73 m²; $P=0.002$). For patients who continued their randomized treatment, the mean difference in eGFR was 11.5 mL/minute/1.73 m² in favor of everolimus plus reduced tacrolimus. Furthermore, the benefit in eGFR was also evident using different formulas (Chronic Kidney Disease Epidemiology Collaboration, Nankivel, and Cockcroft-Gault). For the tacrolimus elimination group, the mean difference in GFR at month 24 versus that in the standard tacrolimus group was 10.4 mL/minute/1.73 m²; 97.5% confidence interval, 5.6–15.3 mL/minute/1.73 m²; $P=0.002$, intent-to-treat population).

**Safety and tolerability**

Overall, everolimus showed a comparable safety profile to standard-of-care treatment in the largest clinical trial comparing everolimus plus reduced tacrolimus with standard-exposure tacrolimus in de novo liver transplant recipients (Figure 3). In clinical trials, specific events such as infections, hyperlipidemia, neutropenia, peripheral edema, stomatitis/mouth ulceration, arterial hypertension, anemia, leukopenia, thrombocytopenia, dry skin, eczema, and rash were more frequent in patients receiving an everolimus-based regimen. More patients randomized to everolimus discontinued study drug than in the control groups, mainly because of adverse events. The following sections summarize the key safety events reported from comparative trials of everolimus in liver transplant recipients.

**Urinary protein excretion**

mTOR inhibitor treatment in general is associated with a net increase in urinary protein excretion. In the H2304 study, in de novo liver transplant recipients, the incidence of proteinuria reported as an adverse event was low overall but was higher in the everolimus plus reduced tacrolimus group than in the standard tacrolimus group (3.7% versus 0.8%, respectively; $P=0.063$), and proteinuria was the leading cause of study drug discontinuation (eight versus one patient). However, the mean urine protein-to-creatinine ratio remained below the 500 mg/day threshold. Of note, renal failure excluding proteinuria was more frequent in the standard tacrolimus group (30.6% versus 21.2% in the everolimus group; $P=0.023$). After CNI withdrawal in the PROTECT study, proteinuria was reported in 9.9% of everolimus-treated patients versus 2.0% of the patients in the CNI group ($P \leq 0.05$). None of the cases of proteinuria were considered severe or serious. In the study of maintenance patients by De Simone et al, two patients discontinued everolimus because of proteinuria, which in both cases was suspected to be related to study medication.

![Figure 2 Mean estimated glomerular filtration rate with everolimus + reduced tacrolimus versus tacrolimus control in the H2304 study.](image)


**Abbreviations:** EVR, everolimus; TAC, tacrolimus; eGFR, estimated glomerular filtration rate.
Everolimus in liver transplantation

Incisional hernia and wound healing complications

A recent systematic review of randomized controlled trials in solid organ transplant recipients reported increased risk for poor wound healing and lymphocelese with immediate use of mTOR inhibitors posttransplant. Willems et al showed that loss of wound strength can be prevented by delaying postoperative administration of everolimus. In the study by Masetti et al, in which everolimus was initiated 10 days after transplantation, incisional hernias were reported more frequently in the everolimus group than with cyclosporine (46.1% versus 26.9%), although the difference was not statistically significant ($P=0.16$). Comparable rates of wound healing complications (11.0% versus 8.3%; $P=0.36$) and incisional hernias (9.8% versus 7.9%; $P=0.52$) with everolimus plus reduced tacrolimus versus standard tacrolimus in the H2304 study suggest that a delay in everolimus introduction can reduce the risk of wound healing complications. Similar results were seen in the PROTECT study, in which rates of incisional hernias (11.9% versus 9.8%) and wound healing complications (2.0% versus 3.9%) were comparable in the everolimus and the CNI groups.

HAT

Early HAT is a well-known complication after liver transplantation. In the H2304 study, 14 cases of HAT were reported during the prerandomization run-in phase. After randomization, one case of HAT was reported in the everolimus plus reduced tacrolimus group, after introduction of everolimus at 30 days posttransplant. This patient had previously experienced an episode of HAT during the run-in period, requiring re-anastomosis of the hepatic artery and stent placement. In the PROTECT study, and in the study by Masetti et al, no cases of HAT were reported in patients converted from a CNI-based to everolimus-based immunosuppression.

Lipid disorders and new-onset diabetes mellitus

Dyslipidemia has been reported in 50%–60% of patients at 3–4 years after liver transplantation. In the H2304 study, hyperlipidemia as an adverse event was reported in a significantly higher proportion of patients in the everolimus group compared with in the tacrolimus control group (26.9% versus 11.6%; $P<0.001$). Similarly, in the PROTECT study, both hyperlipidemia and hypercholesterolemia were
reported more frequently in the everolimus-treated patients than in CNI-treated patients (11.9% versus 2.0% and 22.8% versus 10.8%, respectively; both \(P\leq0.05\)). The relationship between increased dyslipidemia during mTOR inhibitor administration and cardiovascular outcomes has not been systematically evaluated, and thus the clinical effect of these adverse events is not fully understood. However, the proportion of patients receiving lipid-lowering treatment was similar with everolimus plus reduced tacrolimus or the standard-of-care tacrolimus treatment group (23.3% versus 17.8%; \(P=0.944\)) at 1 year posttransplant in the H2304 study. Furthermore, the incidence of cardiovascular events at month 24 did not differ between the two treatment groups (4.1% versus 6.2%; \(P=0.31\)).

Among maintenance patients, hypercholesterolemia and hyperlipidemia were reported more frequently in the everolimus group compared with the CNI group (13.9% versus 2.7% and 9.7% versus 2.7%, respectively), and the difference was significant for hypercholesterolemia (\(P=0.017\)).

NODM has been reported in 26% of liver transplant recipients, and the type of immunosuppressive therapy is one of the predictive factors for NODM after liver transplantation. NODM was reported in 20.8% of patients receiving everolimus plus reduced tacrolimus versus 16.5% of patients receiving standard-exposure tacrolimus at month 24 in the H2304 study (\(P=0.25\)). Similarly, a comparable proportion of patients reported diabetes mellitus with everolimus and CNI (4.0% versus 7.8%) in the PROTECT study.

**Infections**

Infection is a well-recognized, frequent complication associated with immunosuppressive therapy. The incidence of infections varies between studies of everolimus in liver transplantation. In the H2304 study, the overall incidence was 56.3% in the everolimus group versus 51.7% in the tacrolimus control group, with no significant difference between groups. There was a trend toward more bacterial infections in the everolimus group (19.6% versus 13.2% with standard tacrolimus; \(P=0.067\)). Cytomegalovirus infection as an adverse event was reported in 4.9% and 5.4% of patients in the everolimus and tacrolimus treatment groups, respectively (\(P=0.84\)). In the study by Masetti et al, the incidence of major episodes of infections was identical in the everolimus and cyclosporine groups (46.1%), but fungal infections were significantly more frequent with cyclosporine than everolimus (five cases versus one case; \(P=0.011\)). Infections and infestations were more frequent under everolimus therapy than CNI therapy in the PROTECT study (73.3% versus 59.8%). Cytomegalovirus infection was reported in 7.9% of patients in the everolimus group compared with 10.8% patients in the CNI group. In maintenance patients, De Simone et al reported infections in 31.9% of patients in the everolimus group versus 21.9% of patients in the CNI group.

**Peripheral edema**

Edema is a class effect observed with mTOR inhibitors. In the de novo setting (H2304 study), peripheral edema was reported more frequently in the everolimus plus reduced tacrolimus group versus the tacrolimus control group (22.4% versus 14.9%; \(P=0.036\)). Masetti et al reported inferior limb edema in five patients in the everolimus group versus none in the cyclosporine group (\(P=0.16\)). In maintenance patients as well, higher incidence of peripheral edema was reported in everolimus-treated patients compared with in CNI-treated patients (5.6% versus 1.4%), although the difference was not significant.

**Interstitial lung disease**

Intestinal lung disease is a rare but potentially fatal event associated with mTOR inhibitors as a class. In the H2304 study of de novo liver transplant recipients, interstitial lung disease was reported in two patients (0.8%) in both the everolimus plus reduced tacrolimus group and the standard tacrolimus group during the 24-month study period. In the CNI withdrawal setting (PROTECT study), one case of interstitial lung disease was reported in the everolimus group. In maintenance patients, one case of interstitial lung disease suspected to be related to study drug was reported in the everolimus group.

**Stomatitis/mouth ulceration**

Stomatitis/mouth ulceration is one of the common adverse events that has been reported with mTOR inhibitor therapy. In the maintenance setting (H2304 study), the incidence rate of stomatitis was 10.6% in patients receiving everolimus compared with 1.2% in patients receiving standard tacrolimus (\(P<0.001\)). Masetti et al reported aphthous-type mouth ulceration in two everolimus-treated patients, which resolved with dose reduction. In the maintenance setting, De Simone et al reported mouth ulceration in 26.4% of patients who were converted from a CNI-based regimen to everolimus with CNI reduction or discontinuation compared with none of the patients in the CNI continuation group (\(P<0.010\)).
Special liver transplant populations

HCV cirrhosis

There is a lack of robust evidence regarding the ideal immunosuppressive regimen for HCV-positive liver transplant recipients. However, although data are limited, everolimus may offer a benefit for posttransplant HCV-related fibrosis progression. In a subgroup of HCV-positive transplant recipients in the H2304 study, fibrosis progression (defined as 1 or more stage on the Ishak/Knodell score) occurred in fewer everolimus-treated patients compared with patients receiving standard tacrolimus (14/29 [48.3%] versus 22/35 [62.9%]; \(P=0.087\)). In another study conducted in 43 recurrent HCV-positive patients, Villamil et al reported fibrosis progression (1 or more Ishak/Knodell stage) in fewer patients in the everolimus group compared with in the CNI group (1/14 [7.1%] versus 5/18 [27.8%]; \(P=0.060\)). Larger prospective studies in HCV-positive liver transplant recipients are needed to confirm these preliminary findings.

Pediatric liver transplantation

Although there are few reports specifically relating to everolimus in pediatric liver transplant recipients, several studies in renal transplant recipients have shown it can be used safely in children. Nielsen et al reported a single-center experience in which everolimus was given as rescue therapy in 18 pediatric liver transplant recipients, with a median follow-up of 13 months. The indications for use of everolimus were chronic graft dysfunction (N=12), CNI toxicity (N=3), hepatoblastoma (N=2), and recurrence of primary sclerosing cholangitis (N=1). Of the 12 patients treated with everolimus for chronic graft dysfunction, by the end of follow-up, four patients had normal liver function tests and six showed a partial improvement. An increase in GFR was noted in one of the three patients with suspected CNI nephrotoxicity, and patients with hepatoblastoma did not develop any metastasis. No new safety signals were observed. The ongoing H2305 study (NCT01598987) is the first prospective trial of everolimus in pediatric liver transplant recipients. In addition to efficacy and general safety assessments, linear growth, sexual maturation, and hormonal gonadal axis are being closely monitored in this study to assess the potential effect of mTOR inhibition on development in children.

Hepatocellular carcinoma

Everolimus also acts as an antineoplastic agent, and therefore it may exert a beneficial effect in liver transplant recipients with HCC. In a retrospective analysis of 57 patients converted to an everolimus-based regimen mainly because of HCC recurrence (53%) or development of de novo tumors (33%), everolimus was well tolerated in patients with recurrent or de novo malignancies and provided a significant improvement in renal function along with a low rate of acute rejection. Prospective randomized studies are needed to further evaluate the role of everolimus immunosuppression in HCC.

Living donor liver transplantation

Transplantation of a partial liver from a healthy donor to a patient with end-stage liver disease can help address the ongoing problem of donor organ shortage. Studies reporting everolimus use in living-donor liver transplant recipients are scarce. Majeed et al used everolimus as a part of immunosuppressive protocol in patients with HCC undergoing living-donor liver transplantation. However, the focus of the study was to assess predictors of posttransplant survival. In living-donor liver transplant recipients, the efficacy and safety of everolimus plus reduced tacrolimus versus standard-exposure tacrolimus is being evaluated in a 24-month, phase 3, randomized, multicenter study (H2307; NCT01888432).

Quality of life

A systematic review showed that quality of life improves posttransplantation; however, compared with the general population, it still remains impaired. Adverse events associated with long-term exposure to immunosuppressive agents can contribute to this effect. Studies focusing on immunosuppression with everolimus in relation to quality of life and patient satisfaction/acceptability are limited. It will be interesting for future research to focus on the effect of immunosuppressive regimens on health-related quality of life in transplant recipients.

Perspectives

Before the approval of everolimus for use in liver transplantation, perceptions of mTOR inhibitors in this population were predominantly based on experience with sirolimus. Early studies with sirolimus (administered within 48 hours posttransplantation) reported high incidence of serious adverse events including HAT and wound healing complications, which may have been related to the use of loading doses and high maintenance doses (eg, a loading dose of 15 mg followed by 5 mg/day). Importantly, most of the HAT events in sirolimus-treated patients were reported within the first 30 days posttransplantation. As a consequence, sirolimus received a black box warning for use in liver transplantation. Although
Table 2 Summary of key ongoing trials of everolimus in liver transplantation

<table>
<thead>
<tr>
<th>Study</th>
<th>Estimated enrollment</th>
<th>Study population</th>
<th>Study design</th>
<th>Treatment groups</th>
<th>Key endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01888432</td>
<td>470</td>
<td>Living-donor liver transplant recipients (male or female, 18–70 years)</td>
<td>24-month, open-label, multicenter, randomized, controlled trial (Phase II)</td>
<td>EVR + reduced TAC: EVR (C0 3–8 ng/mL plus reduced TAC (C0 3–5 ng/mL with or without corticosteroids) Standard TAC: 8–12 ng/mL until month 4 and decreased by 6–10 ng/mL until end of the study</td>
<td>Composite efficacy failure of tBPAR, graft loss, or death at month 12 postransplantation* Change in eGFR at month 12 AEs and SAEs including infections</td>
</tr>
<tr>
<td>NCT01551212 (HEPHAISTOS)</td>
<td>330</td>
<td>De novo liver transplant recipients (age, 18–65 years)</td>
<td>12-month, open-label, multicenter, randomized, controlled study (phase 3)</td>
<td>EVR: EVR as add-on to tacrolimus TAC: TAC monotherapy</td>
<td>eGFR (Modification of Diet in Renal Disease formula) at month 12* Composite of tBPAR, graft loss, or death Incidence of HCV and HCV-related fibrosis Renal function by eGFR, efficacy failure defined as tBPAR, graft loss, or death, and rate of progression of HCV-related allograft fibrosis at month 36 and 48 postransplantation* Incidence of AEs, SAES, hypertension, neurotoxicity, and NODM</td>
</tr>
<tr>
<td>NCT01150097</td>
<td>266</td>
<td>Liver transplant recipients who completed the core H2304 study with assigned treatment (age, 20–72 years)</td>
<td>Extension study to the open-label, multicenter, randomized, controlled study (phase 3)</td>
<td>EVR + reduced TAC: EVR C0 3–8 ng/mL and TAC C0 3–5 ng/mL EVR: EVR C0 6–12 ng/mL TAC: TAC C0 6–10 ng/mL</td>
<td>Change in eGFR (abbreviated Modification of Diet in Renal Disease formula) at month 6* Treatment failure (BPAR, graft loss, and death) at month 6 Incidence of AEs and SAES at months 3 and 6 BPAR at month 3* Graft survival at month 3* Patient survival at month 3* EVR monotherapy after day 30* Renal function at month 24 Incidence of AEs</td>
</tr>
<tr>
<td>NCT01625377 (SIMCER)</td>
<td>184</td>
<td>De novo liver transplant recipients (age, ≥18 years)</td>
<td>Open-label, multicenter, randomized, controlled study (phase 3)</td>
<td>EVR: EVR (6–12 ng/mL) with gradual reduction of TAC (&lt;5 ng/mL) and possible discontinuation of TAC Control: TAC (6–12 ng/mL) + steroids</td>
<td>Change in eGFR (abbreviated Modification of Diet in Renal Disease formula) at month 6* Treatment failure (BPAR, graft loss, and death) at month 6 Incidence of AEs and SAES at months 3 and 6 BPAR at month 3* Graft survival at month 3* Patient survival at month 3* EVR monotherapy after day 30* Renal function at month 24 Incidence of AEs</td>
</tr>
<tr>
<td>NCT01423708 (EPOCAL)</td>
<td>117</td>
<td>De novo liver transplant recipients (age, 18–70 years)</td>
<td>Prospective, open-label, randomized controlled study (phase 2)</td>
<td>EVR: EVR (6–12 ng/mL) with reduced dose of CsA or TAC (5–12 ng/mL)</td>
<td>Proven acute rejection at month 12* Composite efficacy endpoint (BPAR, graft loss, and death)*</td>
</tr>
<tr>
<td>NCT01807767</td>
<td>100</td>
<td>Liver transplant recipients with Model for End-Stage Liver Disease score ≥ 25 (age, 18–70 years)</td>
<td>Prospective, open-label, randomized controlled study</td>
<td>EVR: EVR (6–12 ng/mL) with MPA 1440 mg/day with TAC withdrawal ± steroids TAC: TAC 6–10 ng/mL with MPA 1,440 mg/day ± steroids</td>
<td>Change in eGFR (abbreviated Modification of Diet in Renal Disease formula) at month 12* Composite efficacy failure rate of tBPAR, graft loss, or death at month 12 Incidence of AEs and SAES at months 12 and 24 eGFR (abbreviated Modification of Diet in Renal Disease formula) at month 12*</td>
</tr>
<tr>
<td>NCT01598987</td>
<td>75</td>
<td>Pediatric liver transplant recipients (male or female, 1 month–17 years)</td>
<td>24-month, open-label, single-group, prospective, multicenter trial (phase 3)</td>
<td>EVR-based regimen: conversion at baseline from immunosuppressive regimen (CsA or TAC ± MPA and corticosteroids) to EVR with reduced dose of CsA or TAC</td>
<td>Proven acute rejection at month 12* Composite efficacy endpoint (BPAR, graft loss, and death)*</td>
</tr>
<tr>
<td>NCT01023542 (BUiLT_01)</td>
<td>45</td>
<td>Liver transplant recipients with Model for End-Stage Liver Disease score ≥ 25 (age, ≥18 years)</td>
<td>Prospective, open-label, randomized controlled study (phase 2)</td>
<td>Delayed CNi: basiliximab 20 mg with MMF (2 g intravenously/day), CsA (day 5 after LTx; 100–150 mg/day), and steroids (1 mg/kg/day from day 0) eliminated by month 6 after LTx</td>
<td>Proven acute rejection at month 12* Composite efficacy endpoint (BPAR, graft loss, and death)*</td>
</tr>
</tbody>
</table>

* Composite efficacy failure of tBPAR, graft loss, or death at month 12 postransplantation

** Composite of tBPAR, graft loss, or death Incidence of graft loss, or death, and rate of progression of HCV-related allograft fibrosis at month 36 and 48 postransplantation Incidence of AEs, SAES, hypertension, neurotoxicity, and NODM

*** Proven acute rejection at month 12
| NCT01707849 | 40 | Liver transplant recipients, RNA-HCV positive within 12 months previous to the transplant (age, ≥18 years) | Unicenter, prospective, randomized, pilot study (phase 3) | Liver fibrosis progression (≥2 under Ishak score) 12-months posttransplant* | Everolimus (EVR) 1 mg twice daily (2–4 ng/mL) + Tacrolimus (TAC) (8–10 ng/mL) MMF: MMF 1 g twice daily + TAC (8–10 ng/mL) |
| NCT00890253 | 29 | De novo liver transplant recipients | Prospective, open-label, single-group, two-stage study (phase 2) | Steroid-resistant rejection at day 30* | Everolimus (EVR) + mycophenolate mofetil (MPA) and complete discontinuation of CNi at 3 months posttransplant |
| NCT01936519 | 24 | Liver transplant recipients (age, 18–70 years) | Randomized prospective trial | Steroid-resistant rejection at 1 year | Everolimus (EVR) Conversion to EVR combined with MPA and complete discontinuation of CNi at 3 months posttransplant |

**Note:** *indicates primary outcome.

**Abbreviations:** EVR, everolimus; TAC, tacrolimus; C0, trough level; tBPAR, treated biopsy-proven acute rejection; HCV, hepatitis C virus; eGFR, estimated glomerular filtration rate; AE, adverse event; SAE, serious adverse event; NODM, new-onset diabetes mellitus; MPA, mycophenolic acid; CNi, calcineurin inhibitor; CsA, cyclosporine; MMF, mycophenolate mofetil; LTx, liver transplantation.
sirolimus is not approved in liver transplantation, recent studies using lower doses have shown an improved safety profile.\textsuperscript{105,106} Today’s target ranges for everolimus (trough level [C0] 3–8 ng/mL in combination with reduced tacrolimus)\textsuperscript{76} and the delay in administration of 30 days posttransplantation have reduced the risk for complications reported in early sirolimus trials. However, in almost all studies, the rate of study drug discontinuations was higher with everolimus than with CNIs. This can be partly explained by the nature of open-label studies testing a new drug against an established drug. The opportunity to achieve CNI reduction with a related improvement in renal function with everolimus-based immunosuppression shown in the large randomized pivotal trial\textsuperscript{76–77} suggests a potential advantage for mTOR inhibitor immunosuppression when introduced at 30 days after liver transplantation.

In adult liver transplant recipients, everolimus has proven to be safe and effective over the course of 2 years’ follow-up.\textsuperscript{77,79} Longer-term outcomes are yet to be investigated in prospectively conducted long-term follow-up studies. The extension phase of H2304 study (H2304E1; NCT01150097) will provide the longer-term renal function and safety outcomes in everolimus-treated patients. Tacrolimus elimination remains an attractive concept, but at present, a benefit has not been proven unequivocally, based on the difference between findings from the H2304 and PROTECT trials. It remains to be confirmed whether everolimus can help to address other unmet needs such as attenuating the progression of graft fibrosis and inhibiting HCC recurrence. Robust safety data will also be needed before everolimus can be used in pediatric patients and living donor transplant recipients. A summary of ongoing trials of everolimus in liver transplantation that will potentially address these unanswered questions is presented in Table 2.

Because everolimus has been shown to provide immunosuppressive efficacy with preservation of renal function preservation in both kidney and liver transplant recipients, its use in combined kidney and liver transplantation may be beneficial considering that a significant proportion of such patients develops renal dysfunction.\textsuperscript{107}

Conclusion, place in therapy

Everolimus provides a new therapeutic option for liver transplant recipients, particularly with respect to posttransplant nephrotoxicity and other adverse events associated with long-term administration of CNIs. Clinical trials have shown that everolimus provides improved protection against renal dysfunction while maintaining immunosuppressive efficacy, particularly when introduced early after liver transplantation. Compared with standard-exposure tacrolimus, everolimus in combination with reduced-dose tacrolimus provides a significant improvement in renal function, sustained over 2 years. The available evidence supports the potentially beneficial effects of everolimus in HCC recurrence and HCV-positive and pediatric liver transplant recipients, although further data from prospective trials are awaited.

Acknowledgment

The authors thank Seema Dimri, Novartis Healthcare Pvt Ltd, India, for providing medical writing/editorial support. The first draft was prepared based on direction from the authors. All authors provided significant input and substantially contributed to the scientific contents. All authors approved the final draft submitted.

Disclosure

Rainer Ganschow and Jörg-Matthias Pollok have received travel grants from Novartis. Guido Junge is an employee of Novartis Pharma AG, Basel, Switzerland. Martin Jankofsky has nothing to disclose.

References


